Classifica tra le azioni
#15162
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Prezzo delle azioni
$3.70
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$369.01M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
35.04%
Scambia Hansa Biopharma AB (HNSBF)
Utile per Hansa Biopharma AB (HNSBF)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Hansa Biopharma AB, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Hansa Biopharma AB dal 2026 al 2026
Utile alla fine di ogni anno
| Anno |
Utile |
Cambia |
|
Non abbastanza dati per le date fornite. |
Utile per aziende simili o concorrenti
| Azienda |
Utile |
Differenza negli utili |
Il paese |
|
|
$1.35B |
-
|
US
|
|
|
- |
-
|
SE
|
|
|
- |
-
|
FR
|
|
|
- |
-
|
IT
|
|
|
$26.37M |
-
|
US
|
